ATE450260T1 - Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden - Google Patents

Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden

Info

Publication number
ATE450260T1
ATE450260T1 AT03718956T AT03718956T ATE450260T1 AT E450260 T1 ATE450260 T1 AT E450260T1 AT 03718956 T AT03718956 T AT 03718956T AT 03718956 T AT03718956 T AT 03718956T AT E450260 T1 ATE450260 T1 AT E450260T1
Authority
AT
Austria
Prior art keywords
tetrahydropyrimidine
phenyl
therapeutic compositions
compositions containing
trifluoromethyl
Prior art date
Application number
AT03718956T
Other languages
English (en)
Inventor
Edward Wei
Original Assignee
Cragmont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cragmont Pharmaceuticals Llc filed Critical Cragmont Pharmaceuticals Llc
Priority claimed from PCT/GB2003/001811 external-priority patent/WO2003092697A1/en
Application granted granted Critical
Publication of ATE450260T1 publication Critical patent/ATE450260T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03718956T 2002-05-02 2003-04-28 Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden ATE450260T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/139,193 US6919348B2 (en) 2002-05-02 2002-05-02 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US10/191,481 US20030207903A1 (en) 2002-05-02 2002-07-08 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction
US10/233,126 US20030206873A1 (en) 2002-05-02 2002-08-29 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for gastrointestinal dysfunction
US10/232,798 US6743801B2 (en) 2002-05-02 2002-08-29 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for pain and inflammation
US10/267,896 US6933301B2 (en) 2002-05-02 2002-10-08 1,2,3,6-tetrahydropyrimidine-2-one compositions, articles and therapeutic methods for upper airway breathing disorders
PCT/GB2003/001811 WO2003092697A1 (en) 2002-05-02 2003-04-28 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith

Publications (1)

Publication Number Publication Date
ATE450260T1 true ATE450260T1 (de) 2009-12-15

Family

ID=29269528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718956T ATE450260T1 (de) 2002-05-02 2003-04-28 Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden

Country Status (4)

Country Link
US (5) US6919348B2 (de)
AT (1) ATE450260T1 (de)
DE (1) DE60330333D1 (de)
ZA (1) ZA200408895B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281751A1 (en) * 1997-07-21 2005-12-22 Bruce Levin Directed intranasal administration of pharmaceutical agents
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
JP2004018470A (ja) * 2002-06-18 2004-01-22 Takasago Internatl Corp 抗菌香料組成物および口臭抑制香料組成物ならびにそれらを含有する口腔用組成物
GB0229811D0 (en) * 2002-12-20 2003-01-29 Unilever Plc Compound delivery systems
US7125497B1 (en) * 2003-05-22 2006-10-24 Sandia Corporation Reactive formulations for a neutralization of toxic industrial chemicals
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20070142367A1 (en) * 2003-11-10 2007-06-21 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20050137166A1 (en) * 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20070155755A1 (en) * 2004-02-23 2007-07-05 Wei Edward T N-arylshydroxyalkylidene-carboxamide compositions and methods
WO2006040103A1 (en) * 2004-10-13 2006-04-20 Bayer Healthcare Ag Use of cold menthol receptor modulators for the treatment of respiratory disorders
WO2006131203A1 (en) * 2005-06-10 2006-12-14 Unilever N.V. Oral care composition comprising a 1 , 2 , 3 , 6-tetrahydropyrimidine-2-one cooling agent
PL1890732T3 (pl) 2005-06-17 2018-11-30 Wisconsin Alumni Research Foundation Preparaty zwężające naczynia krwionośne do podawania miejscowego i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej
WO2007021900A2 (en) * 2005-08-10 2007-02-22 Cutler Robert S Compositions and methods for treating wounds
US20070099237A1 (en) * 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7727516B2 (en) * 2006-02-28 2010-06-01 The Procter & Gamble Company Reduction of hair growth
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) * 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
DE112008002647T5 (de) * 2007-10-02 2010-09-16 Shizuoka Prefectural Universities Corporation Antidiarrhöische Zusammensetzung, Produkte, die diese enthalten, und Verfahren zum Schutz vor Diarrhö
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
WO2009146104A1 (en) * 2008-04-02 2009-12-03 Accentia Biopharmaceuticals, Inc. Formulations, devices and methods for treating and preventing mucositis
ES2759373T3 (es) 2008-06-12 2020-05-08 Medtronic Xomed Inc Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas
AU2009281706A1 (en) * 2008-08-13 2010-02-18 Algometron Pty Ltd Method and device for determining the severity of a pain disorder
CN107375284B (zh) 2008-08-26 2020-08-07 巴斯夫欧洲公司 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途
WO2010042427A2 (en) * 2008-10-06 2010-04-15 Microbial Defense Systems, Llc Antimicrobial composition and methods of making and using same
AU2010255540A1 (en) * 2009-06-05 2012-01-19 Edward Tak Wei Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid
DE102010002558A1 (de) 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
EP2394703B1 (de) 2010-06-14 2015-12-23 Symrise AG Kühlmischungen mit verstärkter Kühlwirkung von 5-Methyl-2-(propan-2-yl)cyclohexyl-N-ethyloxamat
US9029415B2 (en) 2010-06-14 2015-05-12 Symrise Ag Cooling mixtures with an enhanced cooling effect of 5-methyl-2-(propane-2-yl)cyclohexyl-N-ethyloxamate
US9617197B2 (en) 2010-08-04 2017-04-11 University Of Virginia Patent Foundation Compositions and methods for treating inflammatory diseases
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
WO2012098342A1 (en) 2011-01-18 2012-07-26 Paget, Hugh, Charles, Edward (r)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012109216A1 (en) 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
AU2015238807B2 (en) * 2011-02-11 2016-06-23 Sociétés des Produits Nestlé S.A. Multiparticulate l-menthol formulations and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
EP2701681B1 (de) 2011-04-29 2016-10-19 Moberg Pharma AB Pharmazeutische zusammensetzungen mit einem lokalanästhetikum wie bupivacain zur lokalen verabreichung an den mund oder rachen
AU2012253476B2 (en) 2011-05-10 2015-09-24 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
ES2861268T3 (es) 2011-09-20 2021-10-06 Basf Se Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso
CA2909591C (en) * 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
ITMI20132066A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
ES2967435T3 (es) 2017-08-31 2024-04-30 Basf Se Uso de principios activos refrescantes fisiológicos y productos que contienen dichos principios activos
CA3242833A1 (en) 2021-12-17 2023-06-22 Alcon Inc. Ophthalmic pharmaceutical compositions and uses thereof
WO2022207944A2 (en) 2022-07-11 2022-10-06 Symrise Ag Novel mixtures and uses of (2e)-3-(1,3-benzodioxol-5-yl)-n-phenyl-n-(tetrahydro-3-furanyl)-2-propenamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821221A (en) 1970-08-25 1974-06-28 Delmar Chem 1,2,3,6-tetrahydropyrimidine-2-one compounds and processes for makingthem
US3947439A (en) * 1973-03-30 1976-03-30 American Home Products Corporation 4-Hydroxy-4-phenyl-2,3-cycloalkylimino-2-thiazolidinealkylcarboxylic acid lactones
US5116868A (en) 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5215221A (en) * 1992-05-07 1993-06-01 The Procter & Gamble Company Disposable unit dose dispenser for powdered medicants
IL108744A (en) 1994-02-22 1998-12-27 Trop Life Ltd Cylindrical cooling device for medical treatment of hemorrhoids
US5582330A (en) * 1994-12-28 1996-12-10 Allergan, Inc. Specific volume dispenser
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
AU5719798A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9810126D0 (de) * 1998-05-13 1998-07-08 Glaxo Group Ltd
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6391869B1 (en) 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6443152B1 (en) * 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
WO2002081466A1 (en) * 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1474516B1 (de) * 2002-01-25 2013-03-27 The Regents of The University of California Verfahren zur modulation der kältewahrnehmung
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith

Also Published As

Publication number Publication date
US20030206866A1 (en) 2003-11-06
US6919348B2 (en) 2005-07-19
US20030207851A1 (en) 2003-11-06
US6933301B2 (en) 2005-08-23
US20030207904A1 (en) 2003-11-06
ZA200408895B (en) 2006-01-25
DE60330333D1 (de) 2010-01-14
US6743801B2 (en) 2004-06-01
US20030207903A1 (en) 2003-11-06
US20030206873A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
ATE450260T1 (de) Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden
UA84318C2 (ru) Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе
DE602004011394D1 (en) Thiazolderivate
DE60224172D1 (de) Formanilid-derivative als beta2-adrenorezeptor-agonisten
TW200505903A (en) CGRP receptor antagonists
PL376440A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MY135841A (en) Novel benzodioxoles
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
AU2003242544A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
MY131890A (en) Piperidine compounds
AU1192302A (en) Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
YU2803A (sh) 4-fenil-piridin derivati kao antagonisti neurokinin-1 receptora
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
SE0102055D0 (sv) New Compounds
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
MXPA04010860A (es) Composiciones terapeuticas de 1,2,3,6-tetrahidropirimidin-2-ona y metodos para usarla.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties